Stage 1: History of Transient Neurologic Events, Diarrhea & Gross Hematuria (Timestamp: 3 Weeks Prior to Admission)
A 59-year-old male bank executive (residing in Delhi NCR, history of hypertension, dyslipidemia, obesity, OSA on CPAP, 7-pack-year smoking history, moderate alcohol use) presents with 3 weeks of fatigue, light-headedness, and progressive bifrontal headache, followed by sudden transient dizziness, fall, transient nonfluent aphasia, and dark red-tinged urine.
HPI:
- 2 Weeks Ago: 5 days of watery diarrhea with 1 episode of hematochezia.
- Day of Admission: Sudden 3-minute episode of dizziness causing a fall (no loss of consciousness), followed by a 5-minute episode of nonfluent aphasia. Noted new dark, red-tinged urine. No fevers, abdominal pain, nausea, vomiting, rash, or bruising.
- Current Medications: Carvedilol, Lisinopril, Rosuvastatin, Naproxen.
Hello, Chief Resident here.
Key Findings: A 59-year-old male presenting with antecedent bloody diarrhea, acute focal neurological events (transient nonfluent aphasia, fall), and new gross hematuria, on a background of regular NSAID use.
This presentation strongly points toward microvascular occlusion and end-organ dysfunction involving the brain and kidneys following a GI prodrome.
Differential Diagnoses:
1. Thrombotic Microangiopathy (STEC-HUS / aHUS / TTP): 55% – Classic sequence of post-diarrheal renal involvement paired with transient neurological deficits.
2. Embolic TIA/Stroke with Renal Infarction (e.g., Endocarditis / Cardioembolic): 20% – Simultaneous brain and renal ischemia.
3. Systemic Vasculitis (e.g., ANCA-associated / IgA vasculitis): 15% – Multisystem GI, renal, and CNS involvement.
4. NSAID-induced Glomerulonephritis/AKI with independent TIA: 10% – Naproxen toxicity amidst underlying cardiovascular risk factors.
Prioritized Tests:
1. CBC & Peripheral Blood Smear: Check for microangiopathic hemolytic anemia (schistocytes) and thrombocytopenia.
2. Hemolysis Panel & CMP: Creatinine, LDH, haptoglobin, and indirect bilirubin.
3. Urinalysis with Microscopy: Identify dysmorphic RBCs or casts.
4. Brain MRI/MRA: Evaluate for acute ischemic lesions or microvascular damage.
5. ADAMTS13 Activity Level & Stool Shiga-Toxin PCR: Differentiate TTP from STEC-HUS/aHUS.
Hello Attending Consultant here
Critique: Solid TMA prioritization post-diarrheal prodrome with neuro-renal involvement, but underweights cardioembolic sources given vascular risks/OSA/smoking; NSAID link overstated without AKI confirmation. Add echo/blood cultures earlier; defer ADAMTS13 until smear confirms MAHA.
Top 3 DDx:
1. STEC-HUS (post-infectious TMA)
2. Cardioembolic TIA + renal emboli (AF/endocarditis)
3. aHUS/TTP spectrum
Specific points:
1. Urgent CBC/smear for schistocytes/thrombocytopenia.
2. LDH/haptoglobin/bili + Cr for hemolysis/AKI.
3. UA microscopy + culture to confirm glomerular hematuria.
4. Telemetry/ECG + TTE for embolic source.
5. MRI brain + CTA head/neck for infarcts/vasculopathy.
6. Stool Shiga toxin/PCR + blood cultures.
7. Hold naproxen; trend BP/platelets q6h.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Shiga toxin–mediated HUS (STEC-HUS) — a thrombotic microangiopathy unifying the bloody diarrheal prodrome, transient cortical ischemia (aphasia), and glomerular hematuria.
Top Differentials & Fit:
1. STEC-HUS: Fits the sequence perfectly — enteric prodrome → renal + neurologic microvascular injury. Neuro involvement occurs in severe HUS, not just TTP.
2. TTP/aHUS spectrum: Fits identically; distinguished only by ADAMTS13 activity (<10% = TTP) and stool studies. Cannot be separated clinically yet.
3. Cardioembolic disease (AF/endocarditis): Explains simultaneous brain–kidney ischemia and vascular risk profile, but does not explain the diarrheal prodrome; keep on the differential until smear results return.
Key Pivot: The peripheral smear. Schistocytes + thrombocytopenia + hemolysis confirm TMA and collapse the differential; a normal smear redirects urgently toward embolic workup (echo, telemetry, cultures).
Next Move: STAT CBC with smear, LDH/haptoglobin/bilirubin, creatinine, and UA. If MAHA confirmed, send ADAMTS13 before initiating plasma exchange — do not delay PLEX if TTP is clinically plausible. Concurrently obtain ECG/telemetry and TTE.
Teaching Pearl: Neurologic symptoms do not exclude HUS — severe STEC-HUS frequently involves the CNS; let the smear, not the syndrome label, drive the algorithm.
Stage 2: Physical Exam & Severe Thrombocytopenic Microangiopathic Anemia (Timestamp: Admission / Day 1)
Physical Exam: Afebrile (36.3°C), HR 58 bpm (bradycardia on carvedilol), BP 165/95 mmHg, RR 15/min, SpO2 97% on room air. Conjunctival icterus present, oral mucosa dry, no oral bleeding. No lymphadenopathy or rash. Heart/lung exams normal. Abdomen soft, non-tender, no hepatosplenomegaly. Neurologic exam alert, oriented x3, nonfocal.
Initial Laboratory Workup:
- CBC & Reticulocytes: Total WBC 9,940/µL (normal differential), Hemoglobin 8.3 g/dL (Hct 25.6%, MCV 94.8 fL), Platelets 7,000/µL (severe thrombocytopenia!). Reticulocytes 13.2% (marked reticulocytosis!).
- Hemolysis & Hepatic Biomarkers: Total Bilirubin 3.7 mg/dL (Direct 0.4 mg/dL = unconjugated hyperbilirubinemia), LDH 1,401 U/L, Haptoglobin undetectable (<10 mg/dL). AST 104 U/L, ALT 25 U/L. Troponin T 80 ng/L.
- Renal & Coagulation: BUN 24 mg/dL, Creatinine 1.97 mg/dL. PT 15.6s (INR 1.2), aPTT 30.9s, Fibrinogen 312 mg/dL (normal). Urinalysis: 3+ blood, 72 nondysmorphic RBCs/hpf.
Hello, Chief Resident here.
Updated Key Findings: Confirmed Microangiopathic Hemolytic Anemia (MAHA) with severe thrombocytopenia (7,000/µL), high LDH (1,401 U/L), undetectable haptoglobin, mild AKI (Cr 1.97 mg/dL), myocardial injury (troponin 80 ng/L), and normal coags following a diarrheal prodrome.
Profound thrombocytopenia (<30,000/µL) paired with transient neurological deficits strongly shifts likelihood toward TTP over typical STEC-HUS.
Differential Diagnoses:
1. Thrombotic Thrombocytopenic Purpura (TTP): 50% – Marked thrombocytopenia, cardiac/neurologic involvement, and mild renal impairment strongly favor immune or congenital TTP.
2. STEC-HUS: 30% – Classic diarrheal prodrome and AKI, though profound thrombocytopenia is less typical.
3. Atypical HUS (aHUS): 15% – Complement-mediated TMA triggered by an enteric infection.
4. Secondary TMA (Drug-induced/Autoimmune): 5% – Less likely given the clinical sequence.
Prioritized Next Steps:
1. Peripheral Blood Smear: Confirm schistocytes.
2. ADAMTS13 Activity & Inhibitor Screen: Draw STAT before blood product therapy.
3. Stool Shiga Toxin PCR: Rule out STEC.
4. Urgent Management: Initiate Therapeutic Plasma Exchange (TPE) and high-dose glucocorticoids immediately given high risk of mortality; hold naproxen and monitor cardiac telemetry.
Hello Attending Consultant here
Critique: Correct pivot to TTP on profound thrombocytopenia + mild AKI + neuro/cardiac injury, but overstates certainty pre-smear; STEC-HUS still viable post-diarrhea. Initiate PLEX empirically—do not await ADAMTS13. Nondysmorphic RBCs weaken pure glomerular TMA; troponin mandates ACS rule-out.
Top 3 DDx:
1. Immune TTP (ADAMTS13 deficiency)
2. STEC-HUS
3. aHUS (complement-mediated)
Specific points:
1. Confirm schistocytes on STAT smear.
2. Draw ADAMTS13/inhibitor pre-PLEX; start TPE + steroids now.
3. Stool Shiga toxin/PCR + blood cultures.
4. Serial troponin/ECG/telemetry; hold carvedilol if bradycardic.
5. Daily Cr/LDH/platelets; avoid platelet transfusion.
6. CT/MRI brain if neuro recurs; TTE for emboli.
7. Discontinue naproxen; BP control <140/90.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Immune TTP — severe thrombocytopenia (7,000/µL) with disproportionately mild renal injury, neurologic events, and cardiac involvement (troponin 80) is the classic TTP phenotype. The diarrheal prodrome is a recognized trigger of immune TTP flares.
Top Differentials & Fit:
1. Immune TTP: Best fit — platelets <30K with Cr <2.0 strongly favors TTP over HUS; neuro + cardiac microthrombi complete the pentad.
2. STEC-HUS: Diarrheal prodrome fits, but profound thrombocytopenia with only mild AKI argues against it; STEC-HUS is typically renal-dominant.
3. aHUS: Remains possible if ADAMTS13 is normal; consider complement blockade later.
Key Pivot: The platelet-to-creatinine discordance. Severe thrombocytopenia with mild AKI shifts probability decisively from HUS toward TTP — this is the PLASMIC logic in action (score ≥6, high risk).
Next Move: Do NOT wait for ADAMTS13. Start therapeutic plasma exchange + corticosteroids immediately — untreated TTP mortality approaches 90%. Draw ADAMTS13 pre-PLEX, avoid platelet transfusion, hold naproxen, and monitor telemetry for cardiac ischemia.
Teaching Pearl: In TMA, the kidney-to-platelet ratio is your compass: renal-dominant injury suggests HUS; platelet-dominant consumption with neuro/cardiac features demands empiric PLEX for TTP — time is brain, heart, and life.
Stage 3: Direct Antiglobulin Test (Coombs), Smear & PLASMIC Score (MAHA Confirmation) (Timestamp: Hospital Days 1-2)
Diagnostic Evaluations:
- Direct Antiglobulin Test (DAT / Coombs): Negative (rules out autoimmune hemolytic anemia / Evans syndrome).
- Neuroimaging & ECG: Head/Neck CT Angiography normal (no intracranial hemorrhage or arterial occlusion). CXR normal. ECG: Sinus bradycardia with 1st degree AV block.
- Peripheral Blood Smear: Demonstrated numerous Schistocytes / red-cell fragments (~5 per high-power field), polychromasia, nucleated RBCs, and large platelets — establishing Microangiopathic Hemolytic Anemia (MAHA)!
- PLASMIC Score Calculation: Score = 6 / 7 (Platelets <30k, Hemolysis+, INR <1.5, Creatinine <2.0, No cancer, No transplant) -> High Probability of Severe ADAMTS13 Deficiency (iTTP).
Hello, Chief Resident here.
Updated Key Findings: Smear-confirmed Microangiopathic Hemolytic Anemia (MAHA) with abundant schistocytes (~5/HPF), negative Direct Coombs test, and a PLASMIC Score of 6/7, indicating a high probability of severe ADAMTS13 deficiency.
The clinical and laboratory profile overwhelmingly confirms Thrombotic Microangiopathy, with high specificity for Immune TTP.
Differential Diagnoses:
1. Immune TTP (iTTP): 75% – High PLASMIC score, severe thrombocytopenia, mild AKI, negative DAT, and CNS/cardiac microthrombi strongly favor iTTP.
2. Atypical HUS (aHUS): 15% – Complement-mediated TMA remains possible if ADAMTS13 activity returns ≥10%.
3. STEC-HUS: 10% – Antecedent bloody diarrhea, though severe platelet consumption with preserved renal function makes this less likely.
Prioritized Next Steps:
1. Immediate Intervention: Initiate Therapeutic Plasma Exchange (TPE) daily alongside high-dose methylprednisolone without delay.
2. Targeted Therapy: Add Caplacizumab (anti-vWF nanobody) and consider Rituximab early.
3. Diagnostic Confirmation: Await pending ADAMTS13 activity/inhibitor assay and Stool Shiga-toxin PCR.
4. Cardiac & Hematologic Monitoring: Continuous telemetry, serial troponins, and daily CBC/LDH.
5. Transfusion Strategy: Strictly avoid prophylactic platelet transfusions due to risk of worsening microvascular thrombosis.
Hello Attending Consultant here
Critique: Excellent PLASMIC application and empiric TPE urgency; correctly deprioritizes STEC given platelet-Cr discordance. Caplacizumab/rituximab addition is guideline-concordant for iTTP, but confirm ADAMTS13 draw pre-TPE and exclude active bleed before anti-vWF. Mild troponin/AV block still warrants ACS exclusion.
Top 3 DDx:
1. Immune TTP (high-PLASMIC MAHA)
2. aHUS (if ADAMTS13 ≥10%)
3. STEC-HUS (residual post-diarrheal risk)
Specific points:
1. Launch daily TPE + methylprednisolone immediately.
2. Draw ADAMTS13 activity/inhibitor pre-first exchange.
3. Add caplacizumab if no ICH/major bleed; early rituximab.
4. Stool Shiga toxin/PCR + complement panel (C3/C4/AH50).
5. Serial ECG/troponin/telemetry; hold beta-blocker.
6. Daily smear/LDH/platelets/Cr; no platelets unless life-threatening bleed.
7. BP target <140/90; discontinue all nephrotoxins.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Immune TTP (iTTP) — smear-confirmed MAHA, negative DAT, PLASMIC 6/7, severe thrombocytopenia with mild AKI, and neuro-cardiac microthrombi form a near-diagnostic constellation.
Top Differentials & Fit:
1. iTTP: Overwhelming fit — PLASMIC 6 predicts severe ADAMTS13 deficiency with ~90% specificity; DAT negativity excludes Evans syndrome.
2. aHUS: Only viable if ADAMTS13 returns ≥10%; keep complement studies pending.
3. STEC-HUS: Diarrheal prodrome persists as a confounder, but platelet-dominant disease with preserved renal function argues strongly against it.
Key Pivot: The negative DAT combined with schistocytosis. This pairing mechanically confirms MAHA (not immune hemolysis), and the PLASMIC score then stratifies it to TTP — converting a syndromic suspicion into an actionable, time-critical diagnosis.
Next Move: Continue daily TPE + corticosteroids without interruption; add caplacizumab now (no ICH on CTA) and early rituximab for durable remission. Track response with daily platelet counts — platelet recovery >150K × 2 days defines clinical response. Await ADAMTS13 to confirm and guide duration.
Teaching Pearl: PLASMIC is a treatment trigger, not a verdict — a high score mandates empiric PLEX before ADAMTS13 results return, because in TTP the confirmatory test must never delay the life-saving one.
Stage 4: Confirmatory Serologies, Urgent Therapeutic Plasma Exchange (TPE) & Immunosuppression (Timestamp: Hospital Days 3-5)
Emergency Management & Confirmatory Testing:
- Transferred to tertiary care center for urgent Therapeutic Plasma Exchange (TPE) daily + high-dose Methylprednisolone (1 g IV daily x 3 days, then 2.5 mg/kg daily).
- Stool Culture & Shiga Toxin PCR: Negative (rules out STEC-HUS).
- ADAMTS13 Functional Assay: ADAMTS13 Activity <2% (normal >67%) and ADAMTS13 Inhibitor Autoantibody >8.0 Bethesda Units — pathognomonic confirmation of Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP)!
- Anti-CD20 Immunosuppression: Started Rituximab (375 mg/m² weekly x 4 doses).
Hello, Chief Resident here.
Updated Key Findings: Definitive confirmation of Immune Thrombotic Thrombocytopenic Purpura (iTTP) with severe ADAMTS13 deficiency (<2%) and high-titer autoantibody inhibitor (>8.0 BU). STEC-HUS has been definitively excluded by negative stool studies.
Differential Diagnoses:
1. Immune TTP (iTTP): 98% – Pathognomonic confirmation with ADAMTS13 activity <2% and autoantibody inhibitor >8.0 BU.
2. Congenital TTP (Upshaw-Schulman): 1% – Excluded by high autoantibody inhibitor titer.
3. aHUS / Alternative TMA: 1% – Effectively excluded by severe ADAMTS13 deficiency.
Prioritized Management & Next Steps:
1. Continue Daily TPE: Maintain plasma exchange until platelet count is >150,000/µL for at least 2 consecutive days, followed by LDH normalization.
2. Corticosteroid Taper: Complete pulse IV methylprednisolone, then transition to oral prednisone (1 mg/kg/day) with a slow taper after platelet recovery.
3. Complete Rituximab Course: Administer remaining weekly doses (375 mg/m² x 4) to clear inhibitor-producing B-cell clones and reduce relapse risk.
4. Caplacizumab Evaluation: Consider adding caplacizumab (if available) to rapidly halt microvascular thrombosis and lower TPE duration.
5. Serial Monitoring: Daily CBC, LDH, creatinine, and troponin with continuous telemetry until cardiac and hematologic stability is achieved.
Hello Attending Consultant here
Critique: Plan correctly locks onto confirmed iTTP and continues TPE/steroids/rituximab per guidelines. Caplacizumab omission is a gap—add promptly to accelerate platelet recovery and cut TPE days. Congenital TTP already excluded by inhibitor; no need to list. Monitor for TPE complications (citrate toxicity, allergy) and infection risk post-ritux.
Top 3 DDx:
1. Confirmed immune TTP (ADAMTS13 <2% + inhibitor)
2. iTTP with residual cardiac microthrombi
3. Secondary TMA mimic (effectively excluded)
Specific points:
1. Continue daily TPE to platelets >150k ×2 days + LDH normal.
2. Add caplacizumab 11 mg daily (IV then SC) if no major bleed.
3. Complete rituximab 375 mg/m² weekly ×4; check CD19 depletion.
4. Taper steroids post-response; PCP prophylaxis.
5. Serial ADAMTS13 activity q1–2 wk for inhibitor clearance.
6. Telemetry + troponin until normalized; echo if persistent elevation.
7. Vaccinate pre-ritux; counsel lifelong relapse surveillance.
Hello, Expert Clinician here.
Best Unifying Diagnosis: Confirmed immune TTP — ADAMTS13 <2% with inhibitor >8 BU is pathognomonic; the case is now closed diagnostically and shifts entirely to therapeutic optimization and relapse prevention.
Top Differentials & Fit:
1. iTTP: Definitive — inhibitor presence excludes congenital TTP; negative Shiga toxin excludes STEC-HUS.
2. Refractory/relapsing iTTP: The relevant forward-looking concern — high inhibitor titer (>8 BU) predicts slower response and higher relapse risk, justifying aggressive B-cell depletion.
3. TPE-refractory disease: Watch for platelet non-response by day 5–7, which would prompt escalation (e.g., twice-daily TPE, cyclophosphamide, or bortezomib).
Key Pivot: The inhibitor titer. It not only confirms autoimmunity but prognosticates — high-titer disease demands early rituximab (already started) and argues for caplacizumab to bridge the vulnerable pre-response window when fatal thrombotic events cluster.
Next Move: Add caplacizumab immediately if not yet given — it reduces time to platelet recovery, TPE days, and mortality. Continue daily TPE until platelets >150K × 2 days, then serial ADAMTS13 monitoring to detect subclinical relapse before thrombocytopenia recurs.
Teaching Pearl: In iTTP, treatment has three phases — rescue (TPE), shield (caplacizumab), and cure (rituximab); omitting the shield leaves patients unprotected during the deadliest early window.
Stage 5: Refractory Thrombocytopenia, Anti-vWF Nanobody (Caplacizumab) & Complete Recovery (Timestamp: Follow-up & Discharge)
Refractory Course & Targeted Therapy:
- By Hospital Day 9: Platelets remained severely depressed (<20,000/µL) despite daily TPE, steroids, and Rituximab.
- Anti-vWF Nanobody Therapy: Initiated Caplacizumab (11 mg IV/SC daily) on Day 10 to block von Willebrand factor multimer-platelet aggregation.
- Clinical Recovery: Platelets surpassed 50,000/µL within 48 hours of Caplacizumab, reached >150,000/µL by Day 19, and daily TPE was safely discontinued. Discharged on steroid taper + Caplacizumab.
- Outcome: At 3-month follow-up, all medications discontinued, ADAMTS13 activity recovered to normal, and patient remains in complete remission.
Hello, Chief Resident here.
Updated Key Findings: Initially refractory immune TTP successfully rescued with the addition of Caplacizumab on Day 10, leading to complete clinical resolution, sustained platelet recovery, and complete serologic remission (normalized ADAMTS13 activity) at 3-month follow-up.
Diagnosis:
1. Resolved Immune TTP in Complete Remission: 95% – Complete hematologic and immunologic recovery off all therapies.
2. Impending / Subclinical Relapse Risk: 5% – Late autoimmune relapse risk inherent to iTTP history.
Prioritized Long-Term Steps:
1. Serial ADAMTS13 Surveillance: Measure ADAMTS13 activity every 3–6 months for 1–2 years to monitor for subclinical drops.
2. Pre-emptive B-cell Therapy: Plan pre-emptive Rituximab if ADAMTS13 activity drops <20% to prevent overt clinical relapse.
3. Patient Education: Counsel on early warning signs (dark urine, petechiae, neurologic symptoms) requiring an urgent CBC.
4. Post-Rituximab Immunization: Assess B-cell recovery (CD19 count) and update inactivated vaccines as clinically indicated.
This case nicely illustrates the power of Caplacizumab as a life-saving bridge to control microthrombosis while rituximab clears autoantibody production.
Hello Attending Consultant here
Critique: Solid remission confirmation and surveillance plan; correctly flags ADAMTS13 monitoring for pre-emptive ritux. Underemphasizes infection risk post-B-cell depletion and cardiac sequelae (prior troponin rise). Caplacizumab duration was appropriate but counsel on bleeding risk if restarted. Relapse education incomplete without trigger avoidance (infection, pregnancy).
Top 3 DDx:
1. iTTP in sustained complete remission
2. Subclinical ADAMTS13 relapse risk
3. Post-TMA residual microvascular injury (cardiac/renal)
Specific points:
1. ADAMTS13 q3mo ×1yr then q6mo; pre-emptive ritux if <20%.
2. CD19/IgG monitoring; re-vaccinate (pneumococcal, influenza) post-recovery.
3. Echo/troponin if residual symptoms; BP/lipid optimization.
4. Lifelong trigger counseling (infection, surgery, pregnancy).
5. Avoid NSAIDs/estrogen; medic-alert for TTP history.
6. PCP prophylaxis until CD4 recovery if prolonged steroids.
7. Multidisciplinary follow-up (heme + cardio).
Hello, Expert Clinician here.
Best Unifying Diagnosis: iTTP in complete remission — hematologic, clinical, and immunologic recovery (normalized ADAMTS13) achieved through the full three-phase strategy: TPE rescue, caplacizumab shield, rituximab cure.
Top Differentials & Fit:
1. Sustained remission: Most likely — normal ADAMTS13 off therapy at 3 months is the strongest predictor of durable response.
2. Subclinical relapse: The key residual risk — 30–40% of iTTP patients relapse, typically heralded by falling ADAMTS13 weeks before thrombocytopenia; this is the surveillance target.
3. Refractory disease (retrospectively): The Day 9 platelet failure was classic caplacizumab-responsive disease — TPE clears antibody but cannot stop ongoing vWF-platelet aggregation; the nanobody closed that gap.
Key Pivot: Day 10 caplacizumab initiation. Platelets doubled within 48 hours — mechanistic proof that unopposed vWF multimers, not antibody burden alone, drove the refractory phase.
Next Move: Structured ADAMTS13 surveillance every 3 months for 2 years, with pre-emptive rituximab if activity falls below 20% — treating the serologic relapse before the clinical one.
Teaching Pearl: Refractory TTP is often a pharmacologic gap, not treatment failure — TPE removes antibody but caplacizumab neutralizes the substrate; when platelets stall despite exchange, block the vWF-platelet axis rather than escalating immunosuppression blindly.